Treats KRAS G12C-mutated locally advanced or metastatic NSCLC. Sold as Lumakras. Every FDA application for this active ingredient.
As of Nov 15, 2026, FDA lists 1 application for Sotorasib (sold as Lumakras), first approved May 28, 2021, with 1 new use approved and 0 published complete response letters.
| Product | Part | Spending, 2025 | Change | Beneficiaries |
|---|---|---|---|---|
| Lumakras | Part D | $202M | +32% | 2,003 |
| Mitoxantrone Hydrochloride Liposome Combined With Cladribine And Sotorasib For Relapsed Refractory Acute Myeloid LeukemiaRelapsed and Refractory Acute Myeloid Leukemia (RR-AML) · The Affiliated People's Hospital of Ningbo University | Phase 2 | Not yet recruiting | Oct 15, 2026 |
| A 2-part Phase 1/2 Open-label Trial on ODM-212Mesothelioma, Pancreatic Cancer · Orion Corporation, Orion Pharma | Phase 1 / Phase 2 | Recruiting | May 4, 2026 |
| CIMAvax-EGF With KRAS G12C Inhibitor for the Treatment of Advanced, KRAS G12C Mutated Non Small Cell Lung CancerAdvanced Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8 · Roswell Park Cancer Institute | Phase 2 | Not yet recruiting | Apr 21, 2026 |
| ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal CancerDynamic Tumor Resistance, Metastatic Colorectal Cancer · M.D. Anderson Cancer Center | Early phase 1 | Recruiting | Jan 6, 2026 |
| A Rollover Study Evaluating Sotorasib With or Without Panitumumab in Participants With KRAS p.G12C MutationAdvanced Solid Tumors · Amgen | Phase 2 | Recruiting | Sep 15, 2025 |
| 5-fluorouracil Plus Panitumumab (Anti-EGFR) and Sotorasib (KRAS G12C Inhibitor) in First-line Treatment of Patients Non-eligible for a Doublet/Triplet Chemotherapy With Advanced UnresectabColorectal Carcinoma, KRAS G12C Mutation · Federation Francophone de Cancerologie Digestive | Phase 2 | Not yet recruiting | Aug 15, 2025 |
| Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C MutationLocally Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma · National Cancer Institute (NCI) | Phase 1 / Phase 2 | Recruiting | Jun 10, 2025 |
| Sotorasib Combined With First-line Chemotherapy for Advanced Pancreatic AdenocarcinomaPancreatic Adenocarcinoma · Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) | Phase 1 | Recruiting | Mar 24, 2025 |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA